You are here: Industry Insights > Novavax

News List

Novavax COVID-19 Vaccine Shines in Latest Trial drugs
June 15, 2021
Novavax, announced Monday that its two-shot regimen was more than 90 percent effective overall in a trial that unfolded even as more contagious variants emerged.
Novavax COVID-19 Vax is 90% Effective in Phase 3 Trial contractpharma
June 15, 2021
NVX-CoV2373 demonstrates 100% protection against moderate and severe disease, 90% efficacy overall, and met the primary endpoint.
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial prnewswire
June 15, 2021
Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint.
Europe approves SK Bioscience’s global COVID-19 vaccine plant cphi-online
May 27, 2021
CDMO's site becomes the first vaccine production facility in South Korea to obtain EU GMP certification, allowing it to ship to Europe
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update firstwordpharma
May 25, 2021
NVAX today announced that Gregory M. Glenn, M.D., will present on NVX-CoV2373, the company's recombinant nanoparticle COVID-19 vaccine candidate, during the 2021 International Society for Vaccines Virtual Congress 6thCOVID-19 Vaccine Update.
SK bioscience’s COVID-19 vaccine plant in South Korea gets European nod expresspharma
May 18, 2021
The certification approves the production and processing line and quality system of SK bioscience’s Andong plant, which produces COVID-19 vaccines developed by AstraZeneca Plc and Novavax Inc.
Novavax postpones timelines for COVID-19 vaccine production, regulatory authorisations expresspharma
May 12, 2021
The company has repeatedly pushed back production forecasts and has struggled to access raw materials and equipment needed to make its vaccine.
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate worldpharmanews
May 11, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate.
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility prnasia
May 07, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant ...
Paediatric and adolescent COVID-19 vaccines update europeanpharmaceuticalreview
May 07, 2021
The EMA is evaluating whether to lower the age at which Comirnaty can be administered and Novavax has begun testing its COVID-19 vaccine in paediatric patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page